Athena Heart | [310]

Following the ATHENA results, dronedarone was approved with specific administration and safety protocols. : The only recommended dose is 400 mg twice daily .

: Do not use in patients who cannot or will not be converted to sinus rhythm. ATHENA HEART [310]

: The trial established dronedarone as a rhythm-control therapy specifically aimed at reducing clinical complications rather than just maintaining sinus rhythm. 2. Dronedarone (Multaq) Usage Guide Following the ATHENA results, dronedarone was approved with

: Dronedarone significantly reduced the primary composite endpoint of first cardiovascular hospitalization or death by 24% compared to a placebo. : The trial established dronedarone as a rhythm-control

: Classified as Category X ; it may cause fetal harm and should not be used by pregnant women. Drug Interactions :

: Periodic testing is recommended due to reported cases of liver injury.

: Monitor serum creatinine levels; small increases are common but should be assessed if they persist.